Corticosteroids for pneumonia
63 results
1 - 63
Inhaled corticosteroids increase pneumonia risk in stable COPD- Corticosteroids improve outcomes in patients with severe community-acquired pneumonia
- Risk of serious pneumonia in COPD patients using inhaled corticosteroids
- Systemic corticosteroids reduce need for ICU or mechanical ventilation in patients with community-acquired pneumonia
- Steroids = placebo in community acquired pneumonia
- Inhaled steroids for COPD associated with increased risk of pneumonia
- Steroids beneficial as adjunctive treatment for community-acquired pneumonia
- The addition of steroids improves outcomes in children and adults with CAP
- Inhaled budesonide for COPD not associated with pneumonia
- Updated guidelines from the Society of Critical Care Medicine strongly recommend steroids for hospitalized adults with severe community-acquired pneumonia
- A bundle of evidence-based strategies that includes steroids for the treatment of CAP does not improve outcomes
- Single course of antenatal steroids associated with small increased incidence of serious infection in infants
- A single corticosteroid burst in children is associated with harms
- Small study shows steroids may benefit patients with severe CAP and high CRP levels
- Dexamethasone reduces LOS in patients with community-acquired pneumonia
- One year of inhaled corticosteroid use is not associated with frequent serious harms in adults with asthma
- Convalescent plasma does not improve outcomes in patients hospitalized with severe COVID-19 pneumonia (PlasmAr)
- Intravenous hydrocortisone reduces all-cause mortality in severe community-acquired pneumonia (CAPE COD)
- The American Thoracic Society guideline for managing patients with chronic obstructive pulmonary disease
- COVID-19 research briefs: Wuhan patient outcomes, and new Infectious Disease Society of America treatment guidelines
- Updated clinical guidelines for the diagnosis and treatment of CAP
- Subacute cough treatments: limited data, unclear benefits
- Low-dose oral = high-dose IV steroids for initial treatment of acute COPD exacerbation
- Population-based case-finding intervention to identify undiagnosed COPD and asthma has minimal benefits
- Mepolizumab provides only a small reduction in moderate exacerbations when added to triple inhaler therapy for eosinophilic COPD (MATINEE)
- Cyclophosphomide reduces dyspnea in scleroderma lung disease
- Dexamethasone may reduce sore throat symptoms in adults at 48 hours
- Low-dose theophylline is minimally helpful, if at all, in preventing COPD exacerbations
- Canadian Thoracic Society guidelines for pharmacotherapy of stable chronic obstructive pulmonary disease